ClinicalTrials.gg
RecruitingNCT07589647Updated May 27, 2026

Research on the Efficacy and Safety of Targeted Suprachiasmatic Nucleus Electrical Stimulation for Improving Metabolic Disorders in Patients With Stable Bipolar Disorder Comorbid With Obesity

An interventional study of Temporal Interference Stimulation and Sham Temporal Interference Stimulation Arm Description in Bipolar Disorder (BD), sponsored by First Affiliated Hospital of Zhejiang University. Recruiting at 1 site in China. Open to participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2026-05-27.

Sponsored by First Affiliated Hospital of Zhejiang University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2026; still recruiting 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
70
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Bipolar Disorder by First Affiliated Hospital of Zhejiang University — 8 open to participants now, 8 under way, none of them phase 3. Bipolar Disorder · First Affiliated Hospital of Zhejiang University.

Planned enrollment
9th of 12
70 · median 94
Started
2026
with 2 others
No phase
10 of 13
6 open now
Registered
12th of 13
by date

Among the 13 studies in Bipolar Disorder by First Affiliated Hospital of Zhejiang University, this one is the 9th largest by planned enrollment of the 12 interventional ones that give a count, is one of 3 that started in 2026, is one of 10 with no phase, and was the 12th registered.

Bipolar Disorder

1,687 studies on the registry are indexed under Bipolar Disorder; 268 are open to participants now.

Browse Bipolar Disorder studies →

Open to participants now

8 of the 13 studies in Bipolar Disorder by First Affiliated Hospital of Zhejiang University are open now, in 1 country. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

Who these studies take

Of the 207 Bipolar Disorder studies recruiting now, 60 (29%) set no upper age limit and 134 (65%) stop at 75 or younger; 38 take children under 18; 51 take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Bipolar Disorder by First Affiliated Hospital of Zhejiang University, or all of them as a file.
02

Study summary

This study aims to stabilize the patients with bipolar disorder (BD) comorbid with obesity in the stable phase by using temporal interference stimulation (TIS ) intervention. It intends to investigate the changes in key metabolic molecules such as GLP-1 circadian rhythm, and further explore the molecular mechanism of their metabolic disorders.

03

Conditions studied

  • Bipolar Disorder (BD)

Browse trials for

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Both biological parents are of Han ethnicity;
  2. Age range: 18 to 45 years old, gender not restricted;
  3. Meets the clinical diagnostic criteria for bipolar disorder as stipulated in the 5th edition of the (DSM-5);
  4. (BMI) ≥ 28 kg/m2, or for males, waist circumference ≥ 90 cm and for females, waist circumference ≥ 85 cm;
  5. HAMD-24 score \< 7 points, YMRS score \< 5 points;
  6. All included researchers and their family members have given for this study.

Exclusion criteria

Exclusion Criteria:

221/5000

  1. Individuals with other spectrum disorders;
  2. Mental disorders caused by substance abuse (such as alcohol, drugs, etc.), and those with severe physical illnesses;
  3. Those who consumed food or microecological preparations containing probiotics, prebiotics, etc. within one week before enrollment, and had a history of respiratory, urinary, digestive system infections and antibiotic use within one month before enrollment;
  4. Those currently having serious suicidal thoughts or behaviors, or those with severe agitation;
  5. Those who cannot follow medical advice for treatment, or those without guardians;
  6. Pregnant or lactating women, or those planning to become pregnant;
  7. Those who cannot complete MRI examinations due to special conditions such as having metal implants or pacemakers in their bodies.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
70 participants (estimated)

Study arms

  • Experimental
    Temporal Interference Stimulation

    TIS treatment lasts for 20 minutes, with the maximum output current being 2mA, which is adjusted according to the individual head model. The two pairs of electrical stimulation frequencies in tTIS are 1000Hz and 1040Hz.

    Other: Temporal Interference Stimulation

  • Placebo comparator
    Sham Temporal Interference Stimulation

    The stimulus intensity was 20% of MT in the Sham Comparator arm, and the remaining parameters werethe same as the Active Comparator arm.

    Other: Sham Temporal Interference Stimulation Arm Description

Interventions

  • OtherTemporal Interference Stimulation

    TIS treatment lasts for 20 minutes, with the maximum output current being 2mA, which is adjusted according to the individual head model. The two pairs of electrical stimulation frequencies in tTIS are 1000Hz and 1040Hz.

  • OtherSham Temporal Interference Stimulation Arm Description

    The stimulus intensity was 20% of MT in the Sham Comparator arm, and the remaining parameters werethe same as the Active Comparator arm.

06

What researchers measure

Primary outcomes

  1. GLP level

    Time frame: 0-2week

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • 0

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Dec 2026, 8 months after the start.

Of 361 non-industry interventional studies with no phase under Bipolar Disorder, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 58. This study's planned 8 months is below that.

Counting every sponsor, half of 363 studies reached it within 37 months; a quarter within 23 and three quarters within 58.

How these figures are worked out, and which studies are left out of them.

Registered
May 11, 2026
First posted
May 15, 2026
StartActual
Apr 27, 2026
Primary completionEst.
Dec 31, 2026
CompletionEst.
Mar 31, 2027
Last update
May 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07589647
Responsible party
Hu ShaoHua (Department of Psychaitry, The First Affiliated Hospital of Zhejiang University School of Medicine, First Affiliated Hospital of Zhejiang University) — Principal investigator
First posted
May 15, 2026
Start date
Apr 27, 2026
Primary completion
Dec 31, 2026 (estimated)
Completion
Mar 31, 2027 (estimated)
Last update
May 27, 2026

Study contacts

ShaoHua Hu
Contact
dorhushaohua@zju.deu.cn
0571-87232984

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion